Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. (VKTX) on March 29, 2023. The filing discloses the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 17,242,000 shares of Common Stock.
- Public Offering Price: $14.50 per share.
- Underwriting Price: $13.63 per share.
- Gross Proceeds: Approximately $250.0 million (excluding over-allotment).
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 2,586,300 shares at the public offering price, exercisable for 30 days.
- Expected Closing Date: On or about April 3, 2023.
Material Changes and Use of Proceeds
The primary material change is the execution of the Underwriting Agreement with William Blair & Company, L.L.C. The Company intends to use the net proceeds for:
- Continued development of its VK2809, VK2735, and VK0214 programs.
- General research and development.
- Working capital and general corporate purposes.
Additionally, directors and executive officers have entered into lock-up agreements prohibiting the sale of securities until June 27, 2023.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated closing of the Offering and the use of proceeds. Key risks and contingencies include:
- The ability to satisfy customary closing conditions on a timely basis or at all.
- Market and other conditions affecting the transaction.
- The Company explicitly states it does not intend to revise or update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and commissions.
- Confirm whether the underwriters exercise the over-allotment option to purchase the additional 2,586,300 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific representations, warranties, and termination provisions.
- Monitor the Company's periodic reports for updates on the progress of the VK2809, VK2735, and VK0214 development programs funded by this capital raise.